1.
You evaluate a 17-year-old adolescent for depression and recommend to the mother that because the daughter’s symptoms of depression are of moderate severity, her daughter would benefit from pharmacotherapy and, in particular, a selective serotonin reuptake inhibitor (SSRI). The mother is quite concerned about the new U.S. Food and Drug Administration (FDA) black box warning in the prescribing information for SSRIs about an increased risk of suicidal ideation in children, adolescents, and young people who are placed on these medications. You respond by referring to research that has been published concerning this issue. Which of the following statements is correct?